COMMUNICATION
CREB-binding Protein Is a Nuclear Integrator of Nuclear Factor-kappa B and p53 Signaling*

Raj Wadgaonkar, Kathleen M. Phelps, Zaffar Haque, Amy J. Williams, Eric S. Silverman, and Tucker CollinsDagger

From the Vascular Research Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115

    ABSTRACT
Top
Abstract
Introduction
References

Transcriptional coactivators may function as nuclear integrators by coordinating diverse signaling events. Here we show that the p65 (RelA) component of nuclear factor-kappa B (NF-kappa B) and p53 mutually repress each other's ability to activate transcription. Additionally, tumor necrosis factor-activated NF-kappa B is inhibited by UV light-induced p53. Both p65 and p53 depend upon the coactivator CREB-binding protein (CBP) for maximal activity. Increased levels of the coactivator relieve p53-mediated repression of NF-kappa B activity and p65-mediated repression of p53-dependent gene expression. Nuclear competition for limiting amounts of CBP provides a novel mechanism for altering the balance between the expression of NF-kappa B-dependent proliferation or survival genes and p53-dependent genes involved in cell cycle arrest and apoptosis.

    INTRODUCTION
Top
Abstract
Introduction
References

Nuclear factor-kappa B (NF-kappa B)1 is an inducible transcription factor that plays an essential role in the regulation of gene expression in response to inflammatory stimuli (1). It is composed of members of the Rel family (p50, p52, p65 (RelA), c-Rel, and RelB), which share a region of homology known as the Rel homology domain capable of directing DNA binding and mediating dimerization. In most cells, NF-kappa B is found in an inactive form in the cytoplasm bound to an inhibitory protein, Ikappa B. In response to multiple activating signals, the inhibitor is degraded by the ubiquitin-proteasome complex, and NF-kappa B translocates to the nucleus and induces gene expression. NF-kappa B components can interact with other DNA binding proteins, as well as with a series of non-DNA-binding coactivator proteins. Among these interactions, the p65 component of NF-kappa B, like a variety of signal-dependent transcriptional activators, can associate with CREB-binding protein (CBP) or its structural homolog p300 (2, 3).

Activation of NF-kappa B is associated with resistance to programmed cell death (4-10). Mice with a targeted mutation in the p65 component of NF-kappa B die before birth with extensive liver cell apoptosis (11). Fibroblasts derived from these mice show increased apoptosis following TNFalpha stimulation, an effect that can be reversed by overexpression of p65 (4). Inhibition of NF-kappa B activation increases cell death in response to multiple stimuli (7). Moreover, inhibition of constitutively active NF-kappa B in lymphoid cell lines causes apoptosis (8). One mechanism by which NF-kappa B inhibits cell death is to induce the expression of genes that promote resistance to apoptosis. These anti-apoptotic gene include A20 (12), the immediate early response gene IEX-1L (13), as well as TRAF1 (TNFR-associated factor 1), TRAF2, and the inhibitor-of-apoptosis (IAP) proteins c-IAP and c-IAP2 (14). Thus NF-kappa B can activate a set of genes that function cooperatively to suppress apoptosis.

In contrast to NF-kappa B's role in promoting cell survival, the p53 tumor suppressor gene plays an important role in cell cycle arrest or apoptosis in response to various types of stress (15, 16). p53 functions as a transcriptional activator by binding to specific DNA sequence elements (17) and interacting with coactivators, such as CBP (18-21). These interactions appear to be necessary for p53 to function as a transcription factor. p53 increases expression of multiple genes, including the cyclin-dependent kinase inhibitor p21/WAF1/Cip and murine double minute (mdm2) (15, 16, 22, 23). Increased expression of the p21 gene by p53 correlates with cell cycle control by inducing G1 arrest or apoptosis (24). The ability of p53 to induce cell cycle arrest or apoptosis is closely regulated under normal conditions (22, 23). Some oncogenes and stress signals regulate p53 activity through MDM2. This negative regulator of p53 functions in two ways: it binds to the activation domain of p53 and inhibits its ability to stimulate transcription, and MDM2 mediates the degradation of p53. In addition to having a role as a transcriptional activator, p53 represses the expression of multiple genes that lack p53 binding sites (25). In contrast to activation by p53, no common consensus DNA binding site has been identified which correlates with the transcriptional repression. The biological consequences of p53-mediated repression of gene expression are not fully understood.

The divergent roles played by NF-kappa B and p53 suggest that there might be mechanisms that integrate the activities of these regulatory factors. Some of this control may be provided by the common dependence of both NF-kappa B and p53-dependent gene expression on limiting levels of transcriptional coactivators. Since transactivation by both p53 and p65 involves CBP, we investigated the role of this coactivator in the p53 and NF-kappa B signaling pathways. We find that mutual transrepression of these diverse signaling systems results, at least in part, from competition for a limiting amount of this versatile transcriptional coactivator. Interactions between the p65 and p53 signaling pathways mediated by CBP may be an important aspect of regulating the diverse changes in gene expression associated with cell survival.

    EXPERIMENTAL PROCEDURES

Cells and Transfections-- SaoS2 and COS-7 were obtained from the American Type Culture Collection (ATCC). ECV-304 cells were obtained from the European Collection of Animal Cell Cultures (ECACC, Salisbury, Wiltshire, United Kingdom). The cells were cultivated in Dulbecco's modified Eagle's medium from Life Technologies, Inc. supplemented with 10% fetal calf serum, 2 mM L-glutamine, and antibiotics. Cells were grown on 10-cm2 dishes and cultured at 37 °C in a 5% CO2 incubator. The COS cells were cotransfected with -578 E-selectin promoter-CAT (26) or a p21-promoter-luciferase reporter construct (p21-luciferase), along with expression vectors for human p53 (pC53-SN3), p65 (pcDNA p65), MDM2 (pCHDMIA), or CBP (pRc/RSV-mCBP-HA), as described in the figure legends. Whole cell extracts were prepared from the transfected cells and CAT or luciferase activity determined as described previously (2, 27).

Transfected cells were treated with 100 units/ml TNFalpha (Endogene Sciences) for 30 min and then exposed to increasing amounts of ultraviolet light (10, 20, and 40 J/m2) using a Stratalinker (Stratagene) at 254 nm UV. Cells were harvested 4 h after exposure to UV light and whole cell extracts prepared.

Western Blot-- Aliquots from the cotransfection studies were saved prior to the freeze/thaw step in the CAT assay harvesting procedure. Cells were lysed in 5 × cell lysis buffer (Promega, Madison, WI) for 20 min on ice. Samples were centrifuged briefly, and equivalent amounts of protein were resuspended in SDS sample buffer, boiled for 2 min, and analyzed on 10% SDS-polyacrylamide gels. Proteins were electrophoretically transferred to nitrocellulose (Schleicher and Schuell), the membranes blocked with 5% non-fat dry milk in TBST buffer (containing 20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.5% Tween 20), and incubated with either p65 or p53 (Rockland, Gilbertsville, PA and PharMingen, San Diego, CA, respectively) antisera for 16 h at 4 °C. Blots were washed three times with TBST buffer, incubated for 1 h with a secondary antibody conjugated to horseradish peroxidase (Amersham Pharmacia Biotech), and then washed three times in TBST. The antigen antibody interactions were visualized by incubation with ECL chemiluminescence reagent (Amersham Pharmacia Biotech). Blots were exposed to x-ray film for 10 s to 10 min.

    RESULTS AND DISCUSSION

p65 and p53 Mutually Repress Each Other's Transcription-- If CBP functions as a signal integrator for the NF-kappa B and p53 pathways, there might be mutual transcriptional interference between these two signal-dependent activators. To determine whether the p65 component of NF-kappa B alters p53 function, a p53 reporter plasmid containing the p21 promoter, a known p53 target gene associated with arrest of the cell cycle, was cotransfected with a fixed amount of p53 and increasing amounts of a p65 expression plasmid. As expected, p53 strongly activates the p21 promoter (Fig. 1A, lanes 2 and 3). Cotransfection of p65 resulted in a dose-dependent suppression of this reporter plasmid in SaoS2 cells (Fig. 1A, lanes 5-8) or in COS cells (Fig. 1B, lanes 3-5). p65-mediated suppression was also seen with a Bax promoter-reporter, a gene that is associated with the induction of apoptosis, as well as an artificial promoter containing only multiple p53 binding sites (data not shown). In contrast to the p53-dependent genes, no repression of a Gal4-dependent promoter-reporter gene was seen (data not shown). Control studies also demonstrate that overexpressed p65 did not decrease production of p53 from the corresponding expression construct (Fig. 1, A and B, insets).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   p65 and p53 mutually repress each other's transcription in a CBP-dependent manner. A, p65 represses p53-dependent activation of a p21-promoter-reporter. Saos2 cells were cotransfected with 3 µg of a p21 promoter-luciferase reporter, increasing amounts (10 and 20 ng) of p53 alone (lanes 2 and 3), or 20 ng of p53 with increasing amounts (0.1, 0.2, 0.5, 1.0 µg) of a p65 expression vector (lanes 5-8). B, p65 repression of p53-activated gene expression is CBP-dependent. COS cells were transfected with 3 µg of a p21 promoter-luciferase reporter construct, 20 ng of p53 alone (lane 2), or with increasing amounts (0.1, 0.5, or 1.0 µg) of a p65 expression vector, in the absence (lanes 3-5), or presence, of 10 µg of a CBP expression vector (lane 6). C, p53 repression of p65-dependent gene expression is CBP-dependent. COS cells were cotransfected with 2 µg of an E-selectin promoter-CAT reporter construct (-578-CAT), 100 ng of a p65 expression vector alone (lane 2), or with increasing amounts (5, 10, 20, or 35 ng) of a p53 expression vector (lanes 3-6), in the presence or absence of increasing amounts (0.5 and 1.0 µg) of an MDM2 expression vector (lanes 7-9) or increasing amounts (3, 5, 8, or 10 µg) of a CBP expression vector (lanes 10-13). The total concentration of DNA was adjusted to 10 µg/6-cm tissue culture dish with empty pCR3 expression vector. Forty-eight hours post-transfection, luciferase or CAT activities in cell extracts were measured as described previously. Portions of the cellular extracts from A-C were analyzed for p65 and p53 by Western blot analysis (insets). Data presented are representative of at least three independent transfections.

To determine whether p53 could alter NF-kappa B-dependent gene expression, similar studies were done with a NF-kappa B-dependent E-selectin promoter-reporter construct (2, 28), a fixed amount of p65, and increasing amounts of p53. As predicted, p65 results in an induction of the NF-kappa B-dependent reporter gene (Fig. 1C, lane 2). Increasing amounts of p53 resulted in a dose-dependent suppression of p65-mediated transactivation (Fig. 1C, lanes 3-6). This effect was reversed by MDM2 (Fig. 1C, lanes 7-9), an inhibitor of p53 transactivation. Control studies demonstrated that overexpression of MDM2 did not alter levels of p65 (Fig. 1C, insets), although in some experiments it modestly increased p65-dependent gene expression (Fig. 1C, lanes 7-9). MDM2 does not physically interact with p65 (data not shown). The presence of p53 had no effect on nuclear accumulation of NF-kappa B or DNA binding activity, and it did not physically interact with p65 (data not shown). Additionally, p53 did not increase expression of an inhibitor of NF-kappa B, Ikappa B-alpha (data not shown). Thus p65-mediated transcriptional activation is repressed by p53, and p53-dependent gene expression is repressed by p65.

CBP Rescues p53 Inhibited p65-dependent Transactivation-- One possibility suggested by the preceding findings is that the formation of complexes between either p65 or p53 and specific coactivators would reduce the amount of coactivator available for transcriptional activation. If competition for limiting amounts of CBP accounts for the inhibitory effect of p53, then increased levels of the coactivators should restore, or rescue, p65-dependent gene expression. Indeed, the inhibitory effect of p65 on p53-dependent gene expression was completely abolished by cotransfection of a vector expressing CBP (Fig. 1B, lane 6). In a similar manner, the suppression of p53 on p65-dependent gene expression was significantly decreased by CBP (Fig. 1C, lanes 10-13). Control studies demonstrated that CBP overexpression did not alter levels of either p53 (Fig. 1, B and C, insets) or p65 (Fig. 1C, inset). Additionally, overexpression of an irrelevant transcriptional activator, or mutated forms of CBP, did not result in rescue (data not shown). Collectively, these functional studies demonstrate that CBP is limiting for both p65- and p53-dependent transactivation and suggest that CBP can rescue the mutually repressive interaction between the two activators.

TNF-activated NF-kappa B Is Inhibited by UV Light-induced p53-- The mutual transrepression of p53- and p65-dependent gene expression described above was observed with over expressed activators and might not reflect the situation with authentic levels of these transcription factors. To address this important issue, we determined whether TNFalpha -activated NF-kappa B was capable of inhibiting endogenous p53-mediated gene expression. Endothelial cells transfected with an E-selectin promoter-reporter were treated with TNFalpha and exposed to increasing amounts of UV irradiation. As expected, TNFalpha activated expression of the E-selectin promoter-reporter construct (Fig. 2A, lane 2). UV illumination resulted in a dose-dependent suppression of this activity (Fig. 2A, lanes 3-5). Cotransfection of an MDM2 expression plasmid, while significantly inhibiting a p53 transcriptional response (Fig. 3 and data not shown), increased expression from the NF-kappa B-dependent reporter gene (Fig. 2A, lane 6). This suggests that the transcriptional activating capacity of endogenous p53 is required for the suppression of the E-selectin promoter-reporter construct. The inhibitory effect of endogenous p53 on NF-kappa B-dependent gene expression was completely abolished by cotransfection of a vector expressing CBP (Fig. 2A, lane 7). In control studies, levels of beta -galactosidase activity were measured in parallel with the activity of the reporter gene. In contrast to the results with the NF-kappa B-dependent reporter, neither the UV treatment nor cotransfection with either MDM2 or CBP altered the level of beta -galactosidase activity (Fig. 2B). These results are consistent with the possibility that the coactivator rescues endogenous p53-suppressed NF-kappa B-dependent gene expression.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   TNFalpha -activated NF-kappa B activity is suppressed by UV light-induced p53. A, UV irradiation suppresses TNFalpha -activated NF-kappa B activity. ECV-304 endothelial cells were cotransfected with 2 µg of an E-selectin promoter-CAT reporter construct (-578-CAT) and 0.25 µg of a beta -galactosidase expression vector, either alone (lane 1) or in the presence of 1 µg of an MDM2 expression vector (lane 6) or 1 µg of a CBP expression vector (lane 7). Transfected cells were treated with 100 units/ml TNFalpha for 30 min (lane 2) and then some of the cells were exposed to increasing amounts of ultraviolet light (10, 20, and 40 J/m2) (lanes 3-5). Cells were harvested 4 h after exposure to UV light. B, UV irradiation does not alter expression of beta -galactosidase activity. Portions of the cellular extracts described above were analyzed for beta -galactosidase activity. Data presented in A and B are representative of at least three independent transfections.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   UV-induced NF-kappa B activity is suppressed following irradiation. A, UV exposure induces expression of a p53-dependent reporter construct. ECV-304 cells were cotransfected with 2 µg of a p21-promoter-luciferase construct in the presence or absence of 1 µg of an MDM2 expression vector. Treated cells were exposed to 40 J/m2 UV ultraviolet light and cells were harvested at the times indicated following stimulation. B, NF-kappa B activity induced by UV is stimulated by MDM2. ECV-304 cells were transfected with 2 µg of an E-selectin promoter-CAT reporter construct (-578-CAT) in the presence or absence of 1 µg of an MDM2 expression vector. Transfected cells were treated with UV as described above and harvested at the times indicated. The results shown are representative of three separate experiments.

NF-kappa B Activity Is Suppressed following UV Stimulation-- The findings described above predict that if endogenous NF-kappa B and p53 are induced simultaneously they would inhibit each other's transcriptional activity. Because UV irradiation activates both transcription factors (29), we used it as a stimulus to examine the effect of the signaling pathways on each other. UV exposure strongly induces expression of a p21 promoter-reporter construct (Fig. 3A) in a time-dependent manner. In parallel, UV also activated expression of an E-selectin promoter-reporter gene (Fig. 3B). Cotransfection of an MDM2 expression plasmid blocked the p53 transcriptional response (Fig. 3A), while increasing expression of the NF-kappa B-dependent reporter plasmid (Fig. 3B). These results are consistent with the proposal that the transcriptional activity of endogenous NF-kappa B is regulated by p53.

From these studies we suggest that cross-talk between the p53 and NF-kappa B signaling cascades is mediated by CBP. These findings are consistent with observations that the levels of p300 are limiting relative to those of p65 (30) and that developmental processes are sensitive to the overall gene dosage of either CBP or its homolog, p300 (31). The common dependence of both p65 and p53 on CBP/p300 suggests that the coactivators may integrate multiple signaling pathways that converge on these transcription factors. For example, p53 inhibits AP-1-dependent transcription, and overexpression of p300 abolished the ability of p53 to inhibit AP-1 activity (18). Similar interplay was observed between p53 and E2F through the coactivator p300 (32). NF-kappa B-dependent gene expression is also regulated by coactivator competition. The p65 component of NF-kappa B and the glucocorticoid receptor mutually repress each other's ability to activate transcription (33). Increased levels of CBP relieve the inhibition of glucocorticoid-mediated repression of NF-kappa B activity and the NF-kappa B mediated repression of GR activity (27). The results described here indicate that NF-kappa B and p53 mutually repress each other's transcription, not only in vitro, but also in intact cells, and suggest that these signaling systems converge on the coactivators. Collectively, these studies are consistent with proposals that coactivator sequestration can function as a selection mechanism to determine patterns of gene expression (34).

This control process may be important in determining the fate of cells in which both NF-kappa B and p53 are activated. In settings where NF-kappa B is acting as a survival factor, NF-kappa B would induce several genes that promote resistance to apoptosis and entry into cell cycle. Indirectly, through coactivator competition, NF-kappa B would also suppress p53's ability to stimulate genes involved in cell death, such as Bax (35), which might block the survival effect. In the context of cell death, p53 would activate expression of genes involved in apoptosis and suppress the survival signals generated by NF-kappa B-dependent gene expression. This control process could be dysregulated during formation of tumors (36).

Key to understanding this level regulation is determining how CBP can simultaneously integrate the functions of these diverse transcriptional activators. The context in which the transcription factors are positioned in the various target gene promoters may determine their ability to compete for the coactivators and synergistically activate transcription (37). Additionally, CBP-associated proteins, such as p/CAF, may generate a series of distinct coactivator complexes (38). These assemblies could be used differentially by specific groups of transcription factors, limiting cross-talk between signaling pathways.

    ACKNOWLEDGEMENTS

The wild-type p53 expression vector and a p21 promoter-luciferase reporter construct were kindly provided by Dr. B. Vogelstein (The Johns Hopkins University). The human MDM2 expression vector was provided by Dr. A. Levine (Princeton University), a CBP expression vector was provided by R. Goodman (Oregon Health Science Center), and a Bax promoter-reporter construct was provided by J. Reed (La Jolla Cancer Research Foundation).

    FOOTNOTES

* This work was supported by Research Grants HL 35716, HL45462, and PO1 HL 36028 from the National Institutes of Health (to T. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pathology, Brigham and Women's Hospital, 221 Longwood Ave., Boston, MA 02115. Tel.: 617-732-5990; Fax: 617-278-6990; E-mail: tcollins{at}bustoff.bwh.harvard.edu.

The abbreviations used are: NF-kappa B, nuclear factor-kappa B; CAT, chloramphenicol acetyltransferase; CBP, CREB-binding protein; CREB, cAMP-response element-binding protein; TNF, tumor necrosis factor.
    REFERENCES
Top
Abstract
Introduction
References

  1. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu. Rev. Immunol. 16, 225-260[CrossRef][Medline] [Order article via Infotrieve]
  2. Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2927-2932[Abstract/Free Full Text]
  3. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) Science 275, 523-527[Abstract/Free Full Text]
  4. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  5. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[Medline] [Order article via Infotrieve]
  6. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  7. Wang, C. Y., Mayo, M. W., and Baldwin, A. S. (1996) Science 274, 784-787[Abstract/Free Full Text]
  8. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., FitzGerald, M. J., Rothstein, T. L., Sherr, D. H., and Sonenshein, G. E. (1996) EMBO J. 15, 4682-4690[Abstract]
  9. Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S., Jr. (1997) Science 278, 1812-1815[Abstract/Free Full Text]
  10. Bertrand, F., Atfi, A., Cadoret, A., L'Allemain, G., Robin, H., Lascols, O., Capeau, J., and Cherqui, G. (1998) J. Biol. Chem. 273, 2931-2938[Abstract/Free Full Text]
  11. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-170[CrossRef][Medline] [Order article via Infotrieve]
  12. Krikos, A., Laherty, C. D., and Dixit, V. M. (1992) J. Biol. Chem. 267, 17971-17976[Abstract/Free Full Text]
  13. Wu, M. X., Ao, Z., Prasad, K. V., Wu, R., and Schlossman, S. F. (1998) Science 281, 998-1001[Abstract/Free Full Text]
  14. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. (1998) Science 281, 1680-1683[Abstract/Free Full Text]
  15. Ko, L. J., and Prives, C. (1996) Genes Dev. 10, 1054-1072[CrossRef][Medline] [Order article via Infotrieve]
  16. Levine, A. J. (1997) Cell 88, 323-331[Medline] [Order article via Infotrieve]
  17. El-Deiry, W. S., Dern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1, 45-49[Medline] [Order article via Infotrieve]
  18. Avantaggiati, M. L., Ogryzko, V., Garner, K., Giordano, A., Levine, A. S., and Kelly, K. (1997) Cell 89, 1175-1184[Medline] [Order article via Infotrieve]
  19. Gu, W., Shi, X. L., and Roeder, R. G. (1997) Nature 387, 819-823[CrossRef][Medline] [Order article via Infotrieve]
  20. Gu, W., and Roeder, R. G. (1997) Cell 90, 595-606[Medline] [Order article via Infotrieve]
  21. Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., and Livingston, D. M. (1997) Nature 387, 823-827[CrossRef][Medline] [Order article via Infotrieve]
  22. Lane, D. P., and Hall, P. A. (1997) Trends Biochem. Sci. 10, 372-374[CrossRef]
  23. Prives, C. (1998) Cell 95, 5-8[Medline] [Order article via Infotrieve]
  24. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75, 817-825[Medline] [Order article via Infotrieve]
  25. Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9979-9983[Abstract]
  26. Read, M. A., Whitley, M. Z., Gupta, S., Pierce, J. W., Best, J., Davis, R. J., and Collins, T. (1997) J. Biol. Chem. 272, 2753-2761[Abstract/Free Full Text]
  27. Sheppard, K. A., Phelps, K. M., Williams, A. J., Thanos, D., Glass, C. K., Rosenfeld, M. G., Gerritsen, M. E., and Collins, T. (1998) J. Biol. Chem. 273, 29291-29294[Abstract/Free Full Text]
  28. Whitley, M. Z., Thanos, D., Read, M. A., Maniatis, T., and Collins, T. (1994) Mol. Cell. Biol. 14, 6464-6467[Abstract]
  29. Bender, K., Gottlicher, M., Whiteside, S., Rahmsdorf, H. J., and Herrlich, P. (1998) EMBO J. 17, 5170-5181[Abstract/Free Full Text]
  30. Hottigen, M. O., Felzien, L. K., and Nabel, G. J. (1998) EMBO J. 17, 3124-3134[Abstract/Free Full Text]
  31. Yao, T.-P., Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., and Eckner, R. (1998) Cell 93, 361-372[Medline] [Order article via Infotrieve]
  32. Lee, C. W., Sorensen, T. S., Shikama, N., and La Thangue, N. B. (1998) Oncogene 28, 2695-2710[CrossRef]
  33. Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., and Baldwin, A. S., Jr. (1995) Mol. Cell. Biol. 15, 943-953[Abstract]
  34. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Sheng-Cai, L., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414[Medline] [Order article via Infotrieve]
  35. Miyashit, T., and Reed, J. C. (1998) Cell 80, 293-299
  36. Giles, R. H., Peters, D. J. M., and Breuning, M. H. (1998) Trends Genet. 14, 178-183[CrossRef][Medline] [Order article via Infotrieve]
  37. Merika, M., Williams, A. J., Chen, G., Collins, T., and Thanos, D. (1998) Mol. Cell 1, 227-287
  38. Parvin, J. D., and Young, R. A. (1998) Curr. Opin. Genet. Dev. 8, 565-570[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.